Bilastine is another H1 antagonist authorized for the symptomatic management of allergic rhinoconjunctivitis and urticaria.
In allergic rhinoconjunctivitis, bilastine has shown similar efficacy to desloratadine and cetirizine with respect to symptom relief.
In urticaria, bilastine has shown similar efficacy to levocetirizine in the reduction of pruritus and the number of wheals, but it was less effective in the maximum size of wheals.
It is well tolerated, just like the other drugs within its group, but has the inconvenience of not being recommended with food or fruit juice as its absorption is significantly reduced.
It presents more drug interactions and it is much more expensive.